BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17413705)

  • 1. Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
    Matthews GV; Dore GJ
    AIDS; 2007 Mar; 21(6):777-8. PubMed ID: 17413705
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
    Bani-Sadr F; Palmer P; Scieux C; Molina JM
    Clin Infect Dis; 2004 Oct; 39(7):1062-4. PubMed ID: 15472862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment: a tale of two viruses.
    Dieterich DT
    AIDS Read; 2002 Oct; 12(10):448-9. PubMed ID: 12408102
    [No Abstract]   [Full Text] [Related]  

  • 6. Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
    Reijnders JG; Janssen HL
    J Hepatol; 2008 Mar; 48(3):383-6. PubMed ID: 18191272
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Matthews GV; Cooper DA; Dore GJ
    Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou Y; Tubiana R; Thibault V
    N Engl J Med; 2003 Jan; 348(2):177-8. PubMed ID: 12519935
    [No Abstract]   [Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
    Van Bömmel F; Schernick A; Hopf U; Berg T
    Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
    Lehmann C; Wyen C; Fätkenheuer G
    Infection; 2006 Aug; 34(4):234-5. PubMed ID: 16896585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
    van Bömmel F; Wünsche T; Schürmann D; Berg T
    Hepatology; 2002 Aug; 36(2):507-8. PubMed ID: 12143063
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
    TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
    [No Abstract]   [Full Text] [Related]  

  • 13. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
    Jenny-Avital ER
    N Engl J Med; 2006 Jun; 354(23):2506-8; author reply 2506-8. PubMed ID: 16764056
    [No Abstract]   [Full Text] [Related]  

  • 14. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 15. Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
    Tamalet C; Tomei C; Henry M; Solas C; Villacian J; Colson P
    AIDS; 2007 Nov; 21(18):2551-2. PubMed ID: 18025898
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Parienti JJ
    J Antimicrob Chemother; 2009 May; 63(5):1080; author reply 1080-1. PubMed ID: 19158108
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HIV agents. The puzzle of virologic failure with tenofovir.
    TreatmentUpdate; 2004; 16(3):4. PubMed ID: 17216834
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR; Morrow JS
    Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
    Landman GW; Soonawala D
    Clin Infect Dis; 2010 Apr; 50(8):1200; author reply 1200. PubMed ID: 20233045
    [No Abstract]   [Full Text] [Related]  

  • 20. Tenofovir helpful for patients with HBV.
    AIDS Patient Care STDS; 2005 May; 19(5):347. PubMed ID: 15948275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.